Heat-induced radiolabeling and fluorescence labeling of Feraheme nanoparticles for PET/SPECT imaging and flow cytometry

Nature Protocols

Volumn 13, Issue 2, 2018, Pages 392-412

  Yuan, Hushan ^a   Wilks, Moses Q ^a   Normandin, Marc D ^a   El Fakhri, Georges ^a   Kaittanis, Charalambos ^a   Josephson, Lee ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERAHEME NANOPARTICLE; FERUMOXYTOL; N HYDROXYSUCCINIMIDE; NANOPARTICLE; UNCLASSIFIED DRUG; FLUORESCENT DYE; IRON; MAGNETITE; RADIOPHARMACEUTICAL AGENT;

ADSORPTION KINETICS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; EX VIVO STUDY; FLOW CYTOMETRY; FLUORESCENCE; HEAT INDUCED RADIOLABELING; IN VIVO STUDY; ISOTOPE LABELING; LIMIT OF QUANTITATION; MALE; MONOCYTE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCATION SURFACE ADSORPTION; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SYNTHESIS; ANIMAL; CHEMISTRY; FLUORESCENCE IMAGING; HEAT; HUMAN; PROCEDURES;

ANIMALS; FERROSOFERRIC OXIDE; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENT DYES; HOT TEMPERATURE; HUMANS; IRON RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; OPTICAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 85041114880     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2017.133     Document Type: Article

References (51)

1. Coyne, D. W. Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease. Expert Opin. Pharmacother. 10, 2563-2568 (2009).
2. Auerbach, M., Strauss, W., Auerbach, S., Rineer, S. & Bahrain, H. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. Am. J. Hematol. 88, 944-947 (2013).
3. Bashir, M. R., Bhatti, L., Marin, D. & Nelson, R. C. Emerging applications for ferumoxytol as a contrast agent in MRI. J. Magn. Reson. Imaging 41, 884-898 (2015).
4. Farrell, B. T. et al. Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL. Neurology 81, 256-263 (2013).
5. Hamilton, B. E. et al. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1-and T2-weighted MRI in neuroimaging. Am. J. Roentgenol. 197, 981-988 (2011).
6. McCullough, B. J., Kolokythas, O., Maki, J. H. & Green, D. E. Ferumoxytol in clinical practice: implications for MRI. J. Magn. Reson. Imaging 37, 1476-1479 (2013).
7. Chen, F. et al. Chelator-free synthesis of a dual-modality PET/MRI agent. Angew. Chem. Int. Ed. Engl. 52, 13319-13323 (2013).
8. Shi, S. et al. Chelator-free radiolabeling of nanographene: breaking the stereotype of chelation. Angew. Chem. Int. Ed. Engl. 56, 2889-2892 (2017).
9. Freund, B. et al. A simple and widely applicable method to 59Fe-radiolabel monodisperse superparamagnetic iron oxide nanoparticles for in vivo quantification studies. ACS Nano 6, 7318-7325 (2012).
10. Israel, L. L. et al. Surface metal cation doping of maghemite nanoparticles: modulation of MRI relaxivity features and chelator-free 68 Ga-radiolabelling for dual MRI-PET imaging. Mater. Res. Express 2, 095009 (2015).
11. Gaglia, J. L. et al. Noninvasive mapping of pancreatic inflammation in recent-onset type-1 diabetes patients. Proc. Natl. Acad. Sci. USA 112, 2139-2144 (2015).
12. Yilmaz, A. et al. Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: a human study using a multi-parametric cardiovascular magnetic resonance imaging approach. Eur. Heart J. 34, 462-475 (2013).
13. Hasan, D. M. et al. Macrophage imaging within human cerebral aneurysms wall using ferumoxytol-enhanced MRI: a pilot study. Arterioscler. Thromb. Vasc. Biol. 32, 1032-1038 (2012).
14. Chalouhi, N., Jabbour, P. & Hasan, D. Inflammation, macrophages, and targeted imaging in intracranial aneurysms. World Neurosurg. 81, 206-208 (2014).
15. Vellinga, M. M. et al. Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study. J. Magn. Reson. Imaging 29, 774-779 (2009).
16. Maarouf, A. et al. Ultra-small superparamagnetic iron oxide enhancement is associated with higher loss of brain tissue structure in clinically isolated syndrome. Mult. Scler. 22, 1032-1039 (2016).
17. Usman, A. et al. Use of ultrasmall superparamagnetic iron oxide particles for imaging carotid atherosclerosis. Nanomedicine (Lond.) 10, 3077-3087 (2015).
18. Boros, E., Bowen, A. M., Josephson, L., Vasdev, N. & Holland, J. P. Chelate-free metal ion binding and heat-induced radiolabeling of iron oxide nanoparticles. Chem. Sci. 6, 225-236 (2015).
19. Normandin, M. D. et al. Heat-induced radiolabeling of nanoparticles for monocyte tracking by PET. Angew. Chem. Int. Ed. Engl. 54, 13002-13006 (2015).
20. Sîrbulescu, R. F. et al. Mature B cells accelerate wound healing after acute and chronic diabetic skin lesions. Wound Repair Regen. 25, 774-791. (2017).
21. Yuan, H. et al. Heat-induced-radiolabeling and click chemistry: a powerful combination for generating multifunctional nanomaterials. PLoS One 12, e0172722 (2017).
22. Balakrishnan, V. S. et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur. J. Clin. Invest. 39, 489-496 (2009).
23. Jahn, M. R. et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur. J. Pharm. Biopharm. 78, 480-491 (2011).
24. Futterer, S., Andrusenko, I., Kolb, U., Hofmeister, W. & Langguth, P. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J. Pharm. Biomed. Anal. 86, 151-160 (2013).
25. Groman, E. V., Paul, K. G., Frigo, T. B., Bengele, H. & Lewis, J. M. Heat stable colloidal iron oxides coated with reduced carbohydrates and derivatives. US patent 6,599,498 (2003).
26. Maruno, S. et al. Polysaccharide derivative/magnetic metal oxide composite. US patent 6,165,378 (2000).
27. Maruno, S. & Hasegawa, M. Organic matter complex. US patent 5,204,457 (1993).
28. Alcantara, D. et al. Fluorochrome-functionalized magnetic nanoparticles for high-sensitivity monitoring of the polymerase chain reaction by magnetic resonance. Angew. Chem. Int. Ed. Engl. 51, 6904-6907 (2012).
29. Cho, H. et al. Fluorochrome-functionalized nanoparticles for imaging DNA in biological systems. ACS Nano 7, 2032-2041 (2013).
30. Warner, C. L. et al. Manganese doping of magnetic iron oxide nanoparticles: tailoring surface reactivity for a regenerable heavy metal sorbent. Langmuir 28, 3931-3937 (2012).
31. Chakravarty, R., Goel, S., Dash, A. & Cai, W. Radiolabeled inorganic nanoparticles for positron emission tomography imaging of cancer: an overview. Q. J. Nucl. Med. Mol. Imaging 61, 181-204 (2017).
32. Sun, X., Cai, W. & Chen, X. Positron emission tomography imaging using radiolabeled inorganic nanomaterials. Acc. Chem. Res. 48, 286-294 (2015).
33. Goel, S., Chen, F., Ehlerding, E. B. & Cai, W. Intrinsically radiolabeled nanoparticles: an emerging paradigm. Small 10, 3825-3830 (2014).
34. Wunderbaldinger, P., Josephson, L., Bremer, C., Moore, A. & Weissleder, R. Detection of lymph node metastases by contrast-enhanced MRI in an experimental model. Magn. Reson. Med. 47, 292-297 (2002).
35. Thorek, D. L. et al. Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle. Nat. Commun. 5, 3097 (2014).
36. Keliher, E. J. et al. 89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging. Bioconjug. Chem. 22, 2383-2389 (2011).
37. Weissleder, R. et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. Am. J. Roentgenol. 152, 167-173 (1989).
38. Wong, R. M., Gilbert, D. A., Liu, K. & Louie, A. Y. Rapid size-controlled synthesis of dextran-coated, 64Cu-doped iron oxide nanoparticles. ACS Nano 6, 3461-3467 (2012).
39. Liu, K. X. et al. Controllable preparation of ternary superparamagnetic nanoparticles dual-doped with Mn and Zn elements. J. Nanosci. Nanotechnol. 12, 8437-8442 (2012).
40. Chen, S., Alcantara, D. & Josephson, L. A magnetofluorescent nanoparticle for ex vivo cell labeling by covalently linking the drugs protamine and Feraheme. J. Nanosci. Nanotechnol. 11, 3058-3064 (2011).
41. Lu, M., Cohen, M. H., Rieves, D. & Pazdur, R. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am. J. Hematol. 85, 315-319 (2010).
42. Wang, C. et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 314, 2062-2068 (2015).
43. Ning, P., Zucker, E. J., Wong, P. & Vasanawala, S. S. Hemodynamic safety and efficacy of ferumoxytol as an intravenous contrast agents in pediatric patients and young adults. Magn. Reson. Imaging 34, 152-158 (2016).
44. Finn, J. P. et al. Cardiovascular MRI with ferumoxytol. Clin. Radiol. 71, 796-806 (2016).
45. Gahart, B. L., Nazareno, A. R. & Ortega, M. Q. Intravenous Medications: A Handbook for Nurses and Health Professionals 3rd edn 555-556 (Elsevier, 2016).
46. Lacroute, P. & Levoy, M. Fast volume rendering using a shear-warp factorization of the viewing transformation. Computer Graphics Proceedings, Annual Conference Series, 451. (1994).
47. Bar-Shalom, R. et al. SPECT/CT using 67Ga and 111In-labeled leukocyte scintigraphy for diagnosis of infection. J. Nucl. Med. 47, 587-594 (2006).
48. Lou, L. et al. 99mTc-WBC scintigraphy with SPECT/CT in the evaluation of arterial graft infection. Nucl. Med. Commun. 31, 411-416 (2010).
49. Schnell, M. A., Hardy, C., Hawley, M., Propert, K. J. & Wilson, J. M. Effect of blood collection technique in mice on clinical pathology parameters. Hum. Gen. Ther. 13, 155-161 (2002).
50. Harisinghani, M., Ross, R. W., Guimaraes, A. R. & Weissleder, R. Utility of a new bolus-injectable nanoparticle for clinical cancer staging. Neoplasia 9, 1160-1165 (2007).
51. Turkbey, B. et al. A phase I dosing study of ferumoxytol for MR lymphography at 3 T in patients with prostate cancer. Am. J. Roentgenol. 205, 64-69 (2015).